Investor Presentaiton
ENHERTU® Promising antitumor activity in HER2+ mCRC patients
DESTINY-CRC02 study (ASCO 2023)
DESTINY-CRC02 study suggests 5.4 mg/kg is the optimal dose
Best % Change in Sum of
Diameters from Baseline
100.
T-DXd 5.4 mg/kg Q3W Total (N = 82)
80-
60.
40
20
་
-20-
-40.
-60.
HER2 statusa :
IHC 3+
CORR 37.8% [27.3-49.2]b
-80-
IHC 2+/ISH+
Patients
-100-
RAS Mutant
Best minimum change, %
Both doses evaluated confirmed the promising antitumor activity
Best % Change in Sum of
Diameters from Baseline
Daiichi-Sankyo
100-
80.
T-DXd 6.4 mg/kg Q3W Stage 1 (N = 40)
CORR 27.5% [14.6-43.9] b
60
40
20
20
0
-20-
-40-
-60-
-80-
Patients
-100
Best minimum change, %
Antitumor activity (ORR) in patients with and without RAS mutation at the 5.4 mg/kg dose
The most common adverse events seen with ENHERTUⓇ in this study were nausea, fatigue, neutropenia, anemia comparable to the known
profile of T-DXd
■There was no grade ≥3 ILD/pneumonitis cases in the 5.4 mg/kg arm
Efficacy and safety profile of both cohorts favors the 5.4 mg/kg dose
a HER2 status was assessed by central laboratory. b 95% confidence interval. CORR: confirmed objective response rate, IHC: immunohistochemistry, ILD: interstitial lung disease, ISH: in situ hybridization, mCRC: metastatic colorectal cancer
18
Q3W: every 3 weeks, T-DXd: trastuzumab deruxtecan, TEAE: treatment emergent adverse eventsView entire presentation